Silexion Therapeutics Corp (SLXNW) Stock Price & Analysis
Silexion Therapeutics Corp (SLXNW) closed at USD 0.01 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.01; the Oct 15, 2026 session ranged USD 0.01–0.01 on volume of 110,490 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SLXNW.md
Key facts (SLXNW)
- Analysts: None.
Analysts (SLXNW)
Consensus None.
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.03 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 110,490 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (SLXNW)
Wall Street analysts rate SLXNW "None", per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (SLXNW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (SLXNW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 32.05 |
| Current Ratio | 0.94 |
| Total Cash | $2.23M |
| Total Debt | $1.41M |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (SLXNW)
Nexqual rates Silexion Therapeutics Corp's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $2M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$12M (TTM) |
| Efficiency | Mixed — No data |
Ownership (SLXNW)
| Float | 5.56M |
|---|
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (SLXNW)
Silexion Therapeutics Corp is led by Ilan Hadar (age 56), Chairman & CEO, per Nexqual as of October 16, 2026 at 05:11 UTC.
| Chairman & CEO | Ilan Hadar (age 56) |
|---|---|
| EVP of Finance Affairs, CFO & Secretary | Mirit Horenshtein Hadar (age 41) |
| Chief Scientific & Development Officer | Mitchell Shirvan (age 71) |
Major Backers & Investors (SLXNW)
Notable institutional backers of Silexion Therapeutics Corp include Polar Asset Management Partners Inc., Linden Advisors LP, Aristeia Capital, LLC, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Polar Asset Management Partners Inc. | 14.21% |
| Linden Advisors LP | 6.45% |
| Aristeia Capital, LLC | 4.52% |
| Clear Street Group Inc. | 4.17% |
| SECURITY BENEFIT LIFE INSURANCE CO | 2.87% |
| Goldman Sachs | 2.39% |
| Kepos Capital Lp | 1.91% |
| Susquehanna International Group, LLP | 1.76% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLXN | Silexion Therapeutics Corp | USD 0.19 | ▲ 7.39% |
| SMXWW | SMX (Security Matters) Public L | USD 0.01 | ▼ 5.48% |
| CDIOW | Cardio Diagnostics Holdings, Inc. | USD 0.01 | ▼ 28.09% |
| HUBCW | Hub Cyber Security Ltd. Warrant | USD 0.01 | ▼ 22.22% |
| CXAIW | CXApp Inc. | USD 0.03 | ▲ 25.12% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt